An interventional study of Dobutamine stress echocardiography in Transthyretin Amyloid Cardiomyopathy and Aortic Stenosis, sponsored by Steen Hvitfeldt Poulsen. Completed at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Steen Hvitfeldt Poulsen · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Aortic Valve Stenosis with a site in Denmark — 13 open to participants now, 28 under way, none of them phase 3. Aortic Valve Stenosis · Denmark.
Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, this one is the 38th largest by enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2024, is one of 28 with no phase, and was the 65th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →13 of the 73 studies in Aortic Valve Stenosis with a site in Denmark are open now. Recruiting first, the newest first:
Copenhagen University Hospital, Rigshospitalet · Sites in Denmark, Sweden
Ages 18+
Anteris Technologies Ltd. · Sites in Denmark
Ages 18+
Ole De Backer · Sites in Denmark, Belgium, Finland and 3 more countries
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Sahajanand Medical Technologies Limited · Sites in Denmark
Ages 18–99
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 3 · Phase 4 7
First in 2005; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 214 across the 40 interventional studies, 200 across the 33 observational. Of the 37 that completed or were terminated, 10 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 73 have an industry lead sponsor. The 10 most frequent:
Steen Hvitfeldt Poulsen is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Steen Hvitfeldt Poulsen has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Aortic Valve Stenosis with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04913870Institut universitaire de cardiologie et de pneumologie de Québec, University LavalAngiotensin Receptor Blockers in Aortic Stenosis | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT05758662St. Antonius HospitalThe Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration (POPular PET TAVI) | 2027-06 |
| NCT06638268Rigshospitalet, DenmarkTranscatheter AortiC Valve Implantation in aorTic stenosIs CardiogenIc Shock | 2027-07-01 |
| NCT06470022Christian Juhl TerkelsenComparison of Evolut FX Versus Sapien 3 Ultra Resilia. | 2027-07-14 |
Add all 6 to your calendar (.ics) → With an account.
Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective clinical study is to improve the diagnosis of Low-flow low-gradient aortic stenosis (LF/LG AS), in patients with co-existing wild-type transthyretin cardiac amyloidosis (ATTRwt). The main question it aims to answer is whether the classic dobutamine-stress echocardiography can be used to determine AS severity in patients with ATTRwt and LF/LG AS. We will do that by comparing dobutamine stress echocardiography, with the invasively measured aortic valve area (which is considered as the gold standard).
In addition we aim to assess the degree of myocardial fibrosis and amyloid infiltration, assessed by light microscopy and cardiac magnetic resonance (CMRI) and evaluation of myocyte mitochondrial function by high resolution respirometry and their relation to AS severity and hemodynamic response to dobutamine.
Study protocol
A- Baseline assessment: The following will be measured:
B- Catheterization laboratory: The participant will be transferred to the catheterization laboratory after about 1.5-hour recovery period after the end of dobutamine stress echocardiography. The following will be done in the following order:
C- Observation: The participant will then be transferred to our out-patient hospital for observation and the participant is expected to be discharged after 2 hours of observation, if no complications arise.
D- CMRI: All the participants will be evaluated with CMRI for estimation of LV mass, T-1 values, and extracellular volume (ECV). This will be scheduled for a separate visit.
Investigations and procedures
Dobutamine Challenges
Dobutamine challenge will be performed two times at the trial day. The first dobutamine challenge will be performed immediately after the baseline echocardiographic examination. The second dobutamine challenge will be performed no earlier than 2 hours later at the catherization laboratory as described below. Dobutamine, known for its brief half-life of approximately 2 minutes, ensures that its effects diminish rapidly, and the specified two-hour interval guarantees that its influence has subsided.
Dobutamine infusion will be performed with a stepwise dobutamine dosage increase (dosages: 2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in patients with ongoing beta-blocker treatment to ensure an appropriate dobutamine response.
The first dobutamine challenge with echocardiography: Blood pressure, heart rate, and standard echocardiography images will be obtained before the infusion start, at each infusion stage, and during the recovery period after the infusion is omitted.
The second dobutamine challenge with invasive measurements: This will be performed at the catheterization laboratory after the insertion of right and left heart catheters. There must be a minimum of 2 hours between the two dobutamine challenges. Blood pressure, heart rate, and pressure and flow measurements will be obtained before the infusion start, at each infusion stage, and during the recovery period after the infusion is omitted. AVA will be estimated at rest and at each dobutamine dose level using Gorlin formula.
AVAproj :
Both echo- and invasive AVAproj will be calculated using the simplified formula (18):
"AVAproj =AVArest + " " AVApeak- AVArest" /"Qpeak-Qrest" " x (250- Qrest)" For invasive measurements, Q is defined as the directly measured flow rate in ml. per second. For echo-derived AVAproj , Q is defined as the transvalvular flow rate = SV/Ejection time. Here SV is calculated by the LVOTVTI x LVOTarea, and ejection time is measured by CW-Doppler of the valve profile.
For both the invasive and echo-derived AVAproj, the peak measurements are defined as the measurements that are associated with the highest measured gradients during dobutamine stress.
As the estimation of AVAproj requires a sufficient increase of the flow of a minimum 15% from baseline; patients who fail to achieve that will be excluded from the primary analysis (18). However, they will be reported in the study results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Symptomatic patients with co-existing wild-type transthyretin amyloid cardiomyopathy and low-flow low gradient AS.
Diagnostic Test: Dobutamine stress echocardiography
Patients will be investigated with dobutamine stress echocardiography (increasing doses of dobutamine infusion and simulatneous echocardiogarphic evaluation) to assess aortic valve area and projected aortic valve area.
Primary endpoint is agreement between echocardiography-derived AVAproj and the invasively assessed AVAproj.
Time frame: Evaluated at the end of dobutamine infusion.
Agreement between echocardiography-derived AVA and invasively assessed AVA at rest and at different dobutamine infusion levels.
Time frame: Evaluated at rest, at every dobutamine dose-level, and at the end of infusion.
Increase of SVI, LV ejection fraction and LV-global longitudinal strain of 10 % during maximal dobutamine stimulation.
Time frame: Evaluated at the end of dobutamine infusion.
Agreement between echo- and invasively estimated flow and SVI.
Time frame: Evaluated at the end of dobutamine infusion.
Degree of myocardial fibrosis, amyloid infiltration and mitochondrial dysfunction and its relation to AS severity and hemodynamic response to dobutamine
Time frame: CMRI would be performed within a max of 2 months from the trial day.
Change in pulmonary artery wedge pressure and mean pulmonary artery pressure
Time frame: Evaluated at the end of dobutamine infusion.
Complication rate and symptomatic side effects during dobutamine challenge
Time frame: Evaluated after couple of days after trial day with dobutamine infusion.
Ran from Apr 2024 to primary completion in Mar 2026, 23 months.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 23 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Steen Hvitfeldt Poulsen